Genprex Inc.

04/04/2024 | Press release | Archived content

AACR NCI EORTC International Conference 2023 – Completion of Acclaim 1 Dose Escalation: Recommended Phase 2 Dose of Quaratusugene Ozeplasmid Gene Therapy and Osimertinib